[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 49
Citations 0
Letters
August 8, 2012

Abciximab vs Thrombectomy for Reperfusion in Myocardial Infarction—Reply

Author Affiliations
 

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliations: Columbia University Medical Center, New York, New York (Dr Stone; gs2184@columbia.edu); Cardiovascular Research Foundation, New York, New York (Dr Brener); and Beth Israel Deaconess Medical Center, Boston, Massachusetts (Dr Gibson).

JAMA. 2012;308(6):565-567. doi:10.1001/jama.2012.8167

In Reply: Drs Kikkert and Henriques requested information regarding outcomes in the INFUSE-AMI trial according to the presence of diabetes mellitus, specifically in regard to the results of manual thrombus aspiration. The randomized European and Australian Multicenter Evaluative Research on Atrial Fibrillation—Dofetilide (EMERALD) trial (N = 510) previously reported that myocardial perfusion was impaired in patients with diabetes (n = 65) vs those without diabetes after coronary intervention in patients with ST-segment elevation myocardial infarction.1 Conversely, the much larger Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial (N = 3265) found that there were no significant differences in the rates of thrombolysis in myocardial infarction flow or myocardial blush grade after PCI in patients with diabetes (n = 533) vs without diabetes.2

×